Repligen Corporation (RGEN) is a Healthcare stock trading at $131.99 (as of 2026-06-18), with a market capitalization of $6.99B and a trailing P/E of 136.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Repligen develops and commercializes bioprocessing technologies and systems for biological drug manufacturing. Its offerings include Protein A ligand and chromatography products (e.g., affinity resins and OPUS columns), along with filtration systems, dialysis products, and related assay kits, which are used by biopharmaceutical manufacturers.